Ascentage Pharma's Novel Bcl-2 Inhibitor Lisaftoclax Receives Approval from China's NMPA for Treatment of CLL/SLL Patients
Reuters
Jul 10
<a href="https://laohu8.com/S/AAPG">Ascentage Pharma</a>'s Novel Bcl-2 Inhibitor Lisaftoclax Receives Approval from China's NMPA for Treatment of CLL/SLL Patients
Ascentage Pharma Group International has announced that its novel Bcl-2 selective inhibitor, lisaftoclax (APG-2575), has received approval from China's National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously undergone at least one systemic therapy, including Bruton's tyrosine kinase $(BTK.AU)$ inhibitors. This marks lisaftoclax as the first Bcl-2 inhibitor to receive conditional approval and marketing authorization for CLL/SLL treatment in China, and the second such inhibitor approved globally. Developed by Ascentage Pharma, lisaftoclax aims to restore the normal apoptosis process in cancer cells by selectively blocking the antiapoptotic protein Bcl-2. The approval is based on positive results from a pivotal registrational Phase II study, highlighting Ascentage Pharma's capabilities in global clinical development and innovation.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief on July 10, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.